Shire nabbed FDA approval for its new long-acting ADHD drug, becoming the second drugmaker in two days to win a nod in that field. Shire’s drug, Mydayis, has been a long time coming. Previously known ...
The rumors that Teva might attempt to buy Shire are puzzling because such an acquisition would present a huge internal conflict to the combined company: What to do with Shire's Vyvanse and Adderall XR ...
After six months of relentless pursuit, Shire SHPG finally announced that it will acquire Baxalta, Inc. BXLT for $32 billion. The boards of directors of both companies have agreed to the merger. We ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results